TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: PTH levels maintained at <=300 pg/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: CaxP levels maintained at <=55 mg(2)/dl(2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of activated T-lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Drug interactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area and Severity Index for palmoplantar dermatoses (ASIppd)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage radiographic defect depth reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hand volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAMIS test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived QOL
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Comfort rating of HDk lenses
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Satisfaction with lenses
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of lens wear while sleeping
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Late prolonged postoperative hypoxaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement in dysthymia and psychosocial outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Somnolence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attention decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Methylprednisolone concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DLS (Daily Living Skills)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ALS (Adaptive Living Skills)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cumulative rate of adverse cardiovascular events
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in BNP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shorter hospitalization stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Lower incidence in readmissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Social symptoms (Social Responsiveness Scale)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: HSP-70 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plaque adhesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for repair
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean number of additional aftercare sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: response rates
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Aspartate aminotransferase level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: glycemic control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: glycemic hemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Need for additional uterotonic drugs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Expression levels of leukocytic GATA-3 mRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ratios of leukocytic T-bet mRNA/GATA-3 mRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Obesity rates based on BMI and WC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pad use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Accuracy of MR angiography in characterizing carotid stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of binge eating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Full remission from bulimia nervosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Cyclops lesions
Endpoint domain: Adverse events/effects
Primary endpoint: 6-month EQ-5D utility scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Physical Component Summary Scores of the SF-36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Parent knowledge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTSS (Post-Traumatic Stress Symptoms)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cognitive response to dopamine agonist drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Severity of addiction to dopamine-releasing stimulant drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart rate at 2 hours post-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients who converted to sinus rhythm at 2 hours post-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Axillary temperatures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: propofol mg/BIS% ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative analgesic demand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfaction in occupational performance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Activities of Daily Living (ADL) performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Blood Pressure Variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: RA and PA Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FACT-Taxane score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Increased MWT latencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced PVT lapses of attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: speed of induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: abdominal pressure required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nursing assessment of patient discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time interval from induction of labor to delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of hyperbilirubinemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of jaundice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fetal loss
Endpoint domain: Mortality/survival
Primary endpoint: malaria at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean peak inhibition of platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADCS-CGIC cognitive domain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ADCS-CGIC ADL domain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum daily alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement of facial acne
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Circumferential velocity of fiber shortening (Vcf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vcf/ESWS ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Untoward reactions during infusions
Endpoint domain: Adverse events/effects
Primary endpoint: Infusion-related rigors
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma FSH and LH concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Length of stay in the PED
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Ease of use and device acceptance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tool score of Patient Information Leaflets (PILs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: areas of allodynia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: temporal summation to electrical and heat stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee flexion improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: CD22 mean fluorescence intensity in total B cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total B cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of good quality endomicroscopic images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pa(O2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in the area under the plasma volume curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Increased GMD in the MBI group
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Postoperative urinary incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of cervical intraepithelial neoplasia grade II or worse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: reduction of probing pocket depth >6 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean forced expiratory volume in 1 second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: daily insulin dose reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: exercise frequencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in forehead wrinkles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in crow's feet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in pregnancy-related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for medical abortion
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: successful smoking cessation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No severe adverse events reported
Endpoint domain: Adverse events/effects
Primary endpoint: Upregulation of gene expression (TGFβ1, CTGF, COL1A1, COL1A2, COL3A1, lumican)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: normovulatory fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oligoanovulation risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of medical comorbidities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiometabolic conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of behavioral problems (CBCL scores above cutoff)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: biliary malondialdehyde concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: malondialdehyde/total bile acid ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mucin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mucin secretagogue activity of gallbladder bile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Plasma levels of total cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma levels of LDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma levels of HDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Procedure success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minor adverse events (puncture site hematomas/edema)
Endpoint domain: Adverse events/effects
Primary endpoint: Asymptomatic thrombi detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean eating rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total SA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modulation transfer function cut-off frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial function (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: rates of negative behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: academic productivity
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: staff/parent ratings of behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Negative blood cultures
Endpoint domain: Adverse events/effects
Primary endpoint: rejection episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of adverse reactions after FS
Endpoint domain: Adverse events/effects
Primary endpoint: Extent of polymerization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain experienced by women following perineal trauma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean peak aqueous humor level of cefepime
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean level of cefepime in aqueous humor at 12 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak level of TBIL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time interval from ED arrival to triage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time interval from ED arrival to bed assignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Triage accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of MSCTA in assessment of plaque surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of CDU and MSCTA regarding plaque composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of stenosis assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: response variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: well-being actions scores in the interpersonal dimension at 60 days
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: well-being actions scores in the physical dimension at 30 days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Postprandial serum triglyceride excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fasting serum LDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fasting serum ApoB48 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of pancreatic septic necroses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in hepatic venous pressure gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak ACTH concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Freedom from death, stroke, myocardial infarction, and coronary reintervention
Endpoint domain: Mortality/survival
Primary endpoint: Quality-adjusted years of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: survival rates following haemorrhage
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of participants prescribed psychotropic medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of Major Depressive Disorder (MDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global LV function at peak stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mitral annular systolic velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mini Mental State Examination scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Alzheimer's Disease Assessment Scale-cognitive domain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Detection of locally recurrent or residual bladder tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Nonesterified fatty acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Achievement of secondary passive goal
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PIIINP serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: BNP serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LVEDD and LVESD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incident congestive heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incident ischemic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SLE disease activity index (SLE-DAI) score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reductions in alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average MAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of intraocular pressure control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Pain scores 1 hour after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for supplementary intravenous morphine within the first 24 postoperative hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients requiring no analgesic intervention while in the PACU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: propofol ED50
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pre‐induction anxiety level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fear-Avoidance Beliefs Questionnaire physical activity subscale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PT and PTT values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: maximum amplitude on the TEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: ionized calcium and serum magnesium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in blood pressure (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Provider adherence to guidelines for identification and assessment of overweight/obese children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UPDRS Part II score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UPDRS Part III score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Schwab and England Independence Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke
Endpoint domain: Mortality/survival